Described are cross-specific antibody molecules with binding specificity for HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis.
Figure 1 Inhibition of ligand stimulation phosphorylation of EGFR in MDA-MB231 cells and HCT116 cells.
Cells were serum starved before addition of antibody and ligand. Cross-specific antibody (8d7 1f6 2f7, i.e. "2F7") was pre-incubated with recombinant HBEGF for 1 hour before addition to cells. Cells were stimulated for 20 mins before preparation of cell lysates. 30 μg of protein was loaded on SDS-PAGE gel and transferred to nitrocellulose membrane. The membrane was probed with anti pEGFR(Tyr1068)
Figure 2 Inhibition of ligand stimulation phosphorylation of EGFR in LoVo cells.
Cells were serum starved before addition of antibody and ligand. Cross-specific antibody (8d7 1f6 2f7, i.e. "2F7") was pre-incubated with recombinant HBEGF for 1 hour before addition to cells. Cells were stimulated for 20 mins before preparation of cell lysates. 30 μg of protein was loaded on SDS-PAGE gel and transferred to nitrocellulose membrane. The membrane was probed with anti pEGFR(Tyr 1068)
Figure 3 The results of a migration assay on MDA-231 breast carcinoma cell line assessed in the presence of 300 nM cross-specific monoclonal antibodies (8d7 1f6 2f7 i.e. “2F7” or 8d7 1c8 1e9 i.e. “1E9”) or isotype control.
The assay was left for 17 hrs before wound width was measured. The right hand panels showing representative images obtained in the absence of treatment and in the presence of 8d7 1f6 2b3 i.e. "2B3"
Figure 4 The results of an invasion assay of HUVEC cells through matrigel in the presence of 500 nM Bi-specific monoclonal antibody ((8d7 1f6 2f7 i.e. “2F7” or 8d7 1c8 1e9 i.e. “1E9” and negative control antibodies.
The cells were left for 24 hours before being stained by Hoescht and number of invaded cells per field of view counted.
Figure 5 Tube assay analysis of cross-specific antibody.
Huvec cells were seeded in the presence of cross-specific antibodies or control antibodies in wells coated with matrigel. Tube structure was analysed after 17 hrs. Images were taken and branching points around nodes counted. The lower panels show representative images with the upper panel illustrating in barchart format the number of branching points around nodes for untreated cells, cells treated with a control antibody and cells treated with the 8d7 1f6 2f7 antibodies.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1493z | Mouse Anti-HBEGF Recombinant Antibody (clone 25C6) | WB, IHC, Neut | Mouse IgG1 |
MOB-2309MZ | Recombinant Mouse Anti-Human HBEGF Antibody (clone 5H20), Biotin-Conjugated | ICC/IF, IP, WB | Mouse antibody |
HPAB-0593-CN | Human Anti-HBEGF Recombinant Antibody (HPAB-0593-CN) | WB, ELISA, FC, Neut | Chimeric (mouse/human) IgG1 |
VS-0224-XY84 | Rat Anti-Mouse Hbegf Recombinant Antibody (VS-0224-XY84) | ELISA | Rat IgG2a |
VS-0624-FY12 | Human Anti-HBEGF Recombinant Antibody (clone KM3966) | Neut, ADCC, FC | Human IgG1 |
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.